CHMP recommends nine drugs in April – first RSV vaccine nears finish line

Eli Lilly, GSK, and BMS, among others, were the recipients of good news after the EMA committee’s meeting this month. 
Photo: Rob Acket/ema
Photo: Rob Acket/ema
by mikkel aabenhus hemmingsen, translated by daniel pedersen

GSK has taken a large step toward getting the first vaccine against respiratory syncytial virus (RSV), targeting adults in their over-sixties, on the market. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading

CHMP recommends two drugs in May

For subscribers